Patients	O
and	O
Study	O
Design	O

A	O
prospective	O
evaluation	O
of	O
the	O
different	O
CMR	O
parameters	O
for	O
predicting	O
LV	B-Multi-tissue_structure
segmental	O
and	O
global	O
functional	O
recovery	O
was	O
performed	O
in	O
46	O
patients	O
(	O
63	O
+	O
/	O
-	O
10	O
years	O
old	O
,	O
3	O
with	O
previous	O
CABG	O
,	O
35	O
with	O
three	O
-	O
vessel	O
disease	O
,	O
3	O
with	O
one	O
-	O
vessel	O
disease	O
)	O
with	O
LV	B-Multi-tissue_structure
systolic	O
dysfunction	O
(	O
LVEF	O
35	O
+	O
/	O
-	O
8	O
%	O
)	O
before	O
they	O
underwent	O
surgical	O
(	O
n	O
=	O
34	O
)	O
or	O
percutaneous	B-Immaterial_anatomical_entity
(	O
n	O
=	O
12	O
)	O
revascularisation	O
.	O

Sixty	O
patients	O
without	O
contraindications	O
for	O
CMR	O
were	O
screened	O
for	O
the	O
following	O
inclusion	O
criteria	O
:	O
(	O
1	O
)	O
CAD	O
(	O
>	O
70	O
%	O
stenosis	O
in	O
one	O
or	O
more	O
major	O
epicardial	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
)	O
,	O
scheduled	O
for	O
a	O
revascularisation	O
procedure	O
;	O
(	O
2	O
)	O
LVEF	O
<	O
=	O
45	O
%	O
;	O
(	O
3	O
)	O
at	O
least	O
two	O
adjacent	O
segments	O
with	O
wall	B-Multi-tissue_structure
motion	O
abnormalities	O
at	O
rest	O
;	O
and	O
(	O
4	O
)	O
no	O
infarction	O
or	O
revascularisation	O
within	O
the	O
last	O
two	O
months	O
.	O

Patients	O
were	O
included	O
in	O
the	O
study	O
only	O
after	O
a	O
successful	O
and	O
complete	O
coronary	B-Multi-tissue_structure
revascularisation	O
.	O

Of	O
the	O
14	O
patients	O
who	O
did	O
not	O
complete	O
the	O
study	O
,	O
3	O
decided	O
not	O
to	O
undergo	O
the	O
repeated	O
CMR	O
scan	O
or	O
were	O
lost	O
during	O
follow	O
-	O
up	O
;	O
7	O
had	O
significant	O
periprocedural	O
injury	O
(	O
new	O
LGE	B-Pathological_formation
zones	O
on	O
repeated	O
CMR	O
scans	O
and	O
clinically	O
proven	O
periprocedural	O
myocardial	B-Multi-tissue_structure
infarction	O
(	O
MI	O
)	O
or	O
MI	O
between	O
both	O
scans	O
)	O
;	O
3	O
had	O
pacemakers	O
or	O
defibrillators	O
implanted	O
in	O
the	O
period	O
between	O
the	O
MR	O
scans	O
;	O
and	O
1	O
was	O
excluded	O
because	O
of	O
dilated	O
cardiomyopathy	O
with	O
secondary	O
CAD	O
.	O

None	O
of	O
the	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
for	O
technical	O
reasons	O
or	O
image	O
quality	O
.	O

The	O
mean	O
interval	O
between	O
CMR	O
and	O
revascularisation	O
was	O
12	O
+	O
/	O
-	O
13	O
days	O
,	O
and	O
none	O
of	O
the	O
patients	O
presented	O
clinical	O
evidence	O
of	O
infarction	O
during	O
this	O
period	O
.	O

The	O
mean	O
interval	O
between	O
MI	O
and	O
the	O
first	O
CMR	O
was	O
3	O
.	O
6	O
years	O
.	O

In	O
46	O
patients	O
,	O
the	O
extent	O
of	O
regional	O
contractility	O
and	O
LGE	B-Pathological_formation
were	O
determined	O
repeatedly	O
by	O
CMR	O
28	O
+	O
/	O
-	O
4	O
weeks	O
(	O
6	O
months	O
)	O
after	O
revascularisation	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Lithuanian	O
Bioethics	O
Committee	O
(	O
Nr	O
.	O
17	O
)	O
,	O
and	O
informed	O
written	O
consent	O
was	O
obtained	O
from	O
each	O
patient	O
prior	O
to	O
inclusion	O
in	O
the	O
study	O
.	O

